Form 13-F position report

COGNITION THERAPEUTICS INC

Reported by MORGAN STANLEY

CGTX CUSIP 19243B102 Manager CIK 0000895421

Reported 68,373 shares, up 40,500 (145.3%) from the prior quarter.

Reported value 104.8%; share count 145.3% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q3 2026
Shares 68,373 Quarter-end amount reported
Reported value $65,638 Fair value at quarter end
Consecutive quarters held 18 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-06-30 46000
2022-09-30 42000
2022-12-31 45925
2023-03-31 43301
2023-06-30 40020
2023-09-30 31491
2023-12-31 40458
2024-03-31 5460
2024-06-30 4980
2024-09-30 469
2024-12-31 11833
2025-03-31 13074
2025-06-30 9625
2025-09-30 44132
2025-12-31 125993
2026-03-31 21170
2026-06-30 32054
2026-09-30 65638

Quarterly position history

How this manager's reported quarter-end position changed over time.

18 quarters
Quarterly reported position history for COGNITION THERAPEUTICS INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 68,373 +40,500 (145.3%) < 0.01% $65,638 2026-11-13
Q2 2026 Unchanged 27,873 0 (0.0%) < 0.01% $32,054 2026-08-13
Q1 2026 Reduced 27,873 -65,455 (-70.1%) < 0.01% $21,170 2026-05-15
Q4 2025 Added 93,328 +60,638 (185.5%) < 0.01% $125,993 2026-02-13
Q3 2025 Added 32,690 +1,621 (5.2%) < 0.01% $44,132 2025-11-14
Q2 2025 Unchanged 31,069 0 (0.0%) < 0.01% $9,625 2025-08-15
Q1 2025 Added 31,069 +14,196 (84.1%) < 0.01% $13,074 2025-05-15
Q4 2024 Added 16,873 +15,873 (1587.3%) < 0.01% $11,833 2025-02-14
Q3 2024 Reduced 1,000 -2,000 (-66.7%) < 0.01% $469 2024-11-14
Q2 2024 Unchanged 3,000 0 (0.0%) < 0.01% $4,980 2024-08-14
Q1 2024 Reduced 3,000 -18,869 (-86.3%) < 0.01% $5,460 2024-05-15
Q4 2023 Unchanged 21,869 0 (0.0%) < 0.01% $40,458 2024-02-13
Q3 2023 Unchanged 21,869 0 (0.0%) < 0.01% $31,491 2023-11-15
Q2 2023 Unchanged 21,869 0 (0.0%) < 0.01% $40,020 2023-08-14
Q1 2023 Unchanged 21,869 0 (0.0%) < 0.01% $43,301 2023-05-15
Q4 2022 Unchanged 21,869 0 (0.0%) < 0.01% $45,925 2023-02-14
Q3 2022 Unchanged 21,869 0 (0.0%) < 0.01% $42,000 2022-11-14
Q2 2022 New 21,869 +21,869 (0.0%) < 0.01% $46,000 2022-08-15

Who else reported the position

80 managers reported COGNITION THERAPEUTICS INC for Q3 2026.

Managers reporting COGNITION THERAPEUTICS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BIOS Capital Management LP Unchanged 6,000,000 0 16.86% $5,760,000 8 qtrs
DAVENPORT & Co LLC Reduced 4,248,410 -11,101 0.02% $4,078,474 5 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Unchanged 3,438,775 0 < 0.01% $3,301,224 3 qtrs
BlackRock Inc Reduced 1,253,474 -8,519 < 0.01% $1,203,335 9 qtrs
Chescapmanager LLC Unchanged 997,029 0 0.07% $957,148 6 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 911,526 +1,520 < 0.01% $875,525 19 qtrs
RENAISSANCE TECHNOLOGIES LLC Reduced 587,171 -106,117 < 0.01% $563,684 12 qtrs
Hilton Capital Management LLC Unchanged 548,950 0 0.04% $526,992 5 qtrs
VANGUARD FIDUCIARY TRUST CO Unchanged 508,220 0 < 0.01% $487,891 3 qtrs
CM Management LLC Reduced 425,000 -25,000 0.27% $408,000 11 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 13, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
0
None
68,373

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.